17,261 trials
Breast Cancer · Cancer of the Breast · Breast Neoplasm
Primary: The Percentage of Participants With Pathologic Complete Response — 11; 0 percentage of participants
Rheumatoid Arthritis
Primary: Percentage of Participants With an American College of Rheumatology 20 Percent (ACR20) Response at Week 12 — 50.0; 43.6; 38.1; 50.0 Percentage of participants — p=0.558
Breast Cancer
Primary: Tumor Proliferation in Tumor Specimens — 2.17; 2.165 percentage of ki-67 positive cells — p=0.98
Deleterious BRCA1 Gene Mutation · Deleterious BRCA2 Gene Mutation · Loss of Heterozygosity
Primary: Overall Response Rate — 8; 12 Percentage of participants
Respiratory Tract Infection
Primary: Percentage of Maternal Participants With Prespecified Local Reactions by Maximum Severity Within 7 Days After Vaccination — 3.5; 2.6; 5.2; 0.9 Percentage of participants
Prostate Cancer · Prostate Cancer Recurrent
Primary: Mean Prostate Specific Antigen (PSA) Level — 0.61; 0.70; 0.54 ng/mL
Alcohol Dependence
Primary: Percent of Heavy Drinking Days — 56.48; 48.57 percentage of days
HIV Infection · Coronary Heart Disease
Primary: Mean Percent Change in Fasting LDL-cholesterol — 15.0; 41.6 Percent decrease
Breast Cancer · Invasive Breast Cancer
Primary: Change in Baseline of Cancer Cell Protein Levels of Human Epidermal Growth Factor Receptor (HER) Family Members (HER1-4) Following Neoadjuvant Endocrine Therapy. — 1…
Multiple Myeloma
Primary: Induction Feasibility Rate (IFR) — 33 Participants
Allergic Conjunctivitis
Primary: Ocular Itching at 5, 7, and 10 Minutes Post CAC on Day 1 — 2.573; 2.500; 1.217; 2.647 units on a scale
C3 Glomerulopathy (C3G)
Primary: Change From Baseline to Week 26 in the C3G Histologic Index for Disease Activity - Subjects With Elevated C5b-9 — -0.9; -1.0 score on a scale — p=0.9670
Smoking Cessation
Primary: Study 1 - Rate of Participant Completion of Pilot — 4; 5 Participants
Hepatic Cirrhosis · Liver Fibrosis · Nonalcoholic Fatty Liver Disease (NAFLD)
Primary: The Percentage of Participants Who Achieve a ≥ 1-Stage Improvement in Fibrosis Without Worsening of Nonalcoholic Steatohepatitis (NASH) at Week 48 — 28.2; 24.3; 28.2…
Breast - Female · Male Breast Cancer
Primary: Number of Participants With at Least One Grade 3 or 4 Treatment-related Adverse Event — 5; 6 Participants